← Leaderboards
Powel Brown
University Of Tx Md Anderson Can Ctr
$21,822,596
Attributed
$21,822,596
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2014–23$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$21,822,596 · 3
By mechanism
N01$21,822,596 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Dihua Yu$18,443,603
- Abenaa M Brewster$1,367,215
- Yi Xiao$208,272
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsSafetyPreventionDoseMalignant NeoplasmsToxic EffectWomanCancer PreventionBiological MarkersMalignant Breast NeoplasmClinically RelevantTumorPreventiveContractorPharmaceutical PreparationsMeetingsBreastRandomizedBrca1 GenePerformanceNational Cancer InstituteOperative Surgical ProceduresDivision Of Cancer PreventionFunding
Grant awards (39)
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$183,238
N01 · FY2023 · CA · contact PI
PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers-- Targeting the PARP Pathway for the Prevention of Breast Cancer$1,121,090
N01 · FY2022 · CA · contact PI
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$260,813
N01 · FY2022 · CA · contact PI
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION$802,476
N01 · FY2021 · CA · contact PI
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-$635,712
N01 · FY2021 · CA · contact PI
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$321,687
N01 · FY2021 · CA · contact PI
IGF::OT::IGF EFFECT OF ASPIRIN ON BIOMARKERS OF BARRETT'S ESOPHAGUS AFTER SUCCESSFUL ERADICATION OF BARRETT'S ESOPHAGUS WITH RADIOFREQUENCY ABLATION$2,604
N01 · FY2021 · CA · contact PI
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$565,667
N01 · FY2020 · CA · contact PI
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION$388,854
N01 · FY2020 · CA · contact PI
A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER$106,072
N01 · FY2020 · CA · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 4-HYDROXYTAMOXIFEN TOPICAL GEL IN WOMEN WITH MAMMOGRAPHICALLY DENSE BREASTS$95,578
N01 · FY2020 · CA · contact PI
ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL$12,938
N01 · FY2020 · CA · contact PI
Cancer Prevention by Vaccination against Induced Antigens$1,227,167
N01 · FY2019 · CA · contact PI
Repurposing of Macrolide Antibiotic Clarithromycin for the Prevention of Lung and Breast Cancer$918,981
N01 · FY2019 · CA · contact PI
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 4-HYDROXYTAMOXIFEN TOPICAL GEL IN WOMEN WITH MAMMOGRAPHICALLY DENSE BREASTS$790,348
N01 · FY2019 · CA · contact PI
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH$724,140
N01 · FY2019 · CA · contact PI
IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019$204,459
N01 · FY2019 · CA · contact PI
A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER$102,010
N01 · FY2019 · CA · contact PI
IGF::OT::IGF VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST$58,235
N01 · FY2019 · CA · contact PI
ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL$30,339
N01 · FY2019 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$1,241,909
N01 · FY2018 · CA · contact PI
IGF::OT::IGF ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL$865,213
N01 · FY2018 · CA · contact PI
Targeting the RXR Pathway for the Prevention of Triple-Negative Breast Cancer HHSN2612015000181 Task Order 8$778,389
N01 · FY2018 · CA · contact PI
RANK Ligand Inhibition - a Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer HHSN2612015000181 TO: HHSN26100009 PP: 9/17/18 to 3/16/2021$643,386
N01 · FY2018 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$1,130,914
N01 · FY2017 · CA · contact PI
IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019$775,035
N01 · FY2017 · CA · contact PI
IGF::OT::IGF Targeting the mTOR Pathway for the Prevention of Breast Cancer$681,028
N01 · FY2017 · CA · contact PI
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oopherectomy$524,438
N01 · FY2017 · CA · contact PI
IGF::OT::IGF TARGETED CASEIN KINASE INHIBITION AS A BREAST CANCER PREVENTION$508,124
N01 · FY2017 · CA · contact PI
IGF::OT::IGF A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER$382,036
N01 · FY2017 · CA · contact PI
IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT$1,111,811
N01 · FY2016 · CA · contact PI
IGF::OT::IGF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 4-HYDROXYTAMOXIFEN TOPICAL GEL IN WOMEN WITH MAMMOGRAPHICALLY DENSE BREASTS$773,497
N01 · FY2016 · CA · contact PI
IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT$1,108,569
N01 · FY2015 · CA · contact PI
IGF::OT::IGF EFFECT OF ASPIRIN ON BIOMARKERS OF BARRETT'S ESOPHAGUS AFTER SUCCESSFUL ERADICATION OF BARRETT'S ESOPHAGUS WITH RADIOFREQUENCY ABLATION$882,357
N01 · FY2015 · CA · contact PI
IGF::OT::IGF ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL$664,703
N01 · FY2015 · CA · contact PI
IGF::OT::IGF VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST$451,648
N01 · FY2015 · CA · contact PI
IGF::OT::IGF A MULTICENTER PHASE II STUDY OF DOCOSAHEXAENOIC ACID IN PATIENTS WITH A HISTORY OF BREAST CANCER, PREMALIGNANT LESIONS, OR BENIGN BREAST DISEASE$55,882
N01 · FY2015 · CA · contact PI
IGF::OT::IGF CONTRACT ORIENTATION AND KICKOFF MEETING$5,645
N01 · FY2015 · CA · contact PI
Contract HHSN261201200034I - Clinical Prevention Agent Development Program: Early Phase Clinical ResearchPeriod of Performance: 9/24/2012 - 9/23/2017Task Order Title: A Multicenter Phase II Stud$685,604
N01 · FY2014 · CA · contact PI